BioPharmSignal logoBioPharmSignal

Biotech News

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Roivant (ROIV)RoivantClinical readout

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P0.0001) All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100%

Related news

ROIVRoivant2026-02-06 12:00 EST

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

ROIVRoivant2026-08-06 11:00 EST

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

View all latest news

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

ROIVRoivant2026-08-06 11:00 EST

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

ROIVRoivant2026-08-06 11:00 EST

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

ROIVRoivant2026-07-23 20:05 EST

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

ROIVRoivant2026-05-20 11:00 EST

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

ROIVRoivant2026-05-11 20:05 EST

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Stock data

Close
36.30 USD
Market cap
20.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States